Ophthotech Corp., of New York, said it achieved a second $50 million enrollment milestone from Basel, Switzerland-based Novartis Pharma AG as part of the ex-U.S. licensing and commercialization agreement between the two companies focused on the treatment of wet age-related macular degeneration (AMD).